Prodrug peptides with improved pharmacological properties

By developing chemically modified prodrug peptides, the problem of insufficient stability and solubility of glucagon under physiological conditions has been solved, and more effective treatment of hypoglycemia has been achieved. By cleavage and release of parental peptides or peptidomimes in the body, it has been improved. biological properties.

CN111051338BActive Publication Date: 2024-12-03IMMUPHARMA (FRANCE) SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880056622.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-06-29
Filing Date
2018-06-29
Publication Date
2024-12-03
Estimated Expiration
2038-06-29

AI Technical Summary

Technical Problem

The existing glucagon has poor chemical stability and poor water solubility, which makes it difficult to effectively treat hypoglycemia at physiological pH, and there are problems with toxicity and pre-systemic metabolism.

Method used

A chemically modified prodrug peptide was developed to improve its biological properties by cleaving the parental peptide or peptidomimetic in vivo, including enhanced therapeutic index, stability, solubility, reduced toxicity and presystemic metabolism. The prodrug peptide comprises a specific amino acid sequence, such as (Glu-Pro)m or (Lys-Pro)X, and at least one Lys is functionalized by a soluble compound to improve its stability and solubility under physiological conditions.

Benefits of technology

It significantly improves the chemical stability and water solubility of glucagon, reduces toxicity and pre-systemic metabolism, enhances the therapeutic index, and is effectively used to treat hypoglycemia-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002395593660000251
    Figure BDA0002395593660000251
  • Figure BDA0002395593660000281
    Figure BDA0002395593660000281
  • Figure BDA0002395593660000291
    Figure BDA0002395593660000291
Patent Text Reader

Abstract

The present disclosure relates to a prodrug peptide, or a salt thereof, having an improvement in at least one biological property compared to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of: therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism. The prodrug peptide comprises the following structure: Z-pep, wherein: pep is a parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo to release pep; n≥2 amino acids. The present disclosure also relates to methods for preparing and using the prodrug peptides of the present disclosure. For example, the present disclosure describes a prodrug peptide that can be used to prevent, treat or improve at least one symptom of hypoglycemia or a hypoglycemia-related disease or condition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] The present disclosure claims priority to U.S. Provisional Patent Application No. 62 / 526,678, filed on June 29, 2017, entitled “Prodrug Peptides with Improved Pharmacological Properties,” the entire contents of which are incorporated herein by reference for all purposes.

[0003] Join by reference

[0004] An electronic version of the sequence listing is submitted herewith, file name: 1513195_131US2_Sequence_Listing_26JUN2018_ST25.txt, size: 13.0 KB, containing SEQ ID NOs: 1-31, the entire contents of which are incorporated herein by reference. Background Art 1. Technical Field

[0006] The present disclosure relates to prodrug peptides, the preparation of the prodrug peptides and their use in treating diseases. In particular, the present disclosure relates to a prodrug peptide comprising a parent peptide or peptidomimetic and a prodrug portion, wherein the prodrug portion comprises at least two amino acids, and the at least two amino acids are cleaved in vivo to release the parent peptide or peptidomimetic.

[0007] 2. Background Information

[0008] Prodrug is a compound that is metabolized by the subject to form a pharmaceutically active compound or drug after administration. The general purpose of prodrug is to cover up undesirable properties. For example, stimulation or pain after topical application, chemical instability, low target selectivity, low solubility in water or lipid membranes, toxicity, pre-systemic metabolism, etc. Therefore, prodrug modifications are especially designed to optimize the adsorption, distribution, metabolism, excretion and / or undesirable toxicity of the parent compound or drug. As a result, prodrugs are especially used to optimize therapeutic index, reduce toxicity, improve adsorption, reduce pre-systemic metabolism, improve solubility and improve chemical stability.

[0009] Prodrugs can be divided into two major categories: type 1 prodrugs and type II prodrugs. Type I prodrugs (e.g., antiviral nucleoside analogs) are prodrugs that are bioactivated intracellularly, where type IA is metabolized at the cellular target of its therapeutic action, and type IB is converted by metabolic tissues (e.g., liver). Type II prodrugs (e.g., salicin) are bioactivated extracellularly, where type IIA is converted in gastrointestinal fluids, type IIB is converted in extracellular fluid compartments (e.g., circulatory system), and type IIC is converted near or inside the therapeutic target / cell.

[0010] Glucagon is a 29-amino acid peptide hormone produced by pancreatic alpha cells in response to low blood glucose levels, thereby stimulating glycogenolysis (i.e., glycogen [n] Broken down into glucose-6-phosphate and glycogen [n-1] ) and gluconeogenesis (i.e., the synthesis of glucose from non-carbohydrate carbon substrates) and inhibit glycogenesis (i.e., the synthesis of glycogen from sugars). As a result, blood sugar increases rapidly.

[0011] Due to the low therapeutic index of insulin, insulin-dependent diabetes is a well-known risk factor for severe hypoglycemia (where blood sugar levels can drop below 50 mg / dl). The standard treatment for hypoglycemia (e.g., severe insulin-induced hypoglycemia) is acute subcutaneous administration of glucagon. However, due to the poor chemical stability of glucagon, glucagon is provided in the form of a lyophilized powder, which is prepared immediately before administration. In addition, due to the poor water solubility of glucagon at physiological pH values, an administration solution is prepared with dilute hydrochloric acid aqueous solution. At the same time, due to the chemical instability of glycogen, glucagon prepared with dilute hydrochloric acid must be used immediately.

[0012] Therefore, there is a need for a method of preparing therapeutic agents with enhanced chemical stability, water solubility, therapeutic index and adsorption, as well as reduced toxicity and pre-systemic metabolism. For example, there is a need for a glucagon prodrug with enhanced chemical stability and water solubility at physiological pH relative to the parent peptide glucagon, which is used as a therapeutic intervention, for example, hypoglycemia. Summary of the invention

[0013] The present specification provides therapeutic compositions and methods for preparing and using the same, based on the surprising and unexpected discovery that the chemically modified peptides described herein have an improvement in at least one biological property (e.g., a biological property that improves and enhances its therapeutic effect) compared to the parent peptide or peptidomimetic (i.e., unmodified peptide). The modified peptides or peptidomimetic described herein include a prodrug portion that is cleaved in vivo to release the parent peptide or peptidomimetic after administration. The peptides and compositions comprising an effective amount of the peptides can effectively treat, prevent and / or ameliorate the symptoms of diseases and conditions, which are treated, prevented or improved by releasing the parent peptide or peptidomimetic (e.g., releasing glucagon or its analogs to treat diseases or conditions associated with hypoglycemia). Therefore, in certain other aspects, the present disclosure provides methods for preparing and using the peptides and compositions comprising the peptides, which are used to treat, prevent and / or improve the symptoms of hypoglycemia-related diseases or conditions.

[0014] Therefore, in one aspect, the present disclosure provides a prodrug peptide or a salt thereof (e.g., a pharmaceutically acceptable salt thereof) having an improvement in at least one biological property compared to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of: therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism, the prodrug peptide comprising the following structure:

[0015] Z n -pep,

[0016] Wherein, pep is the parent peptide or peptidomimetic; Z is a prodrug portion, such as an amino acid sequence of n amino acids; wherein Z is cleaved in vivo to release pep; and n is an integer number of amino acids ≥2.

[0017] In some embodiments, Z has the following structure: (Glu-Pro) m or (Lys-Pro) X , where X is an integer ≥1.

[0018] In certain embodiments, at least the first Lys of Z is functionalized with a soluble compound or moiety.

[0019] In a particular embodiment, at least two Lys groups of Z are functionalized with soluble compounds or moieties.

[0020] In other embodiments, Z comprises 2 amino acids, and the first amino acid is functionalized with a soluble compound or moiety.

[0021] In other embodiments, the soluble compound is hydrophilic or soluble in aqueous solution.

[0022] In a further embodiment, Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.

[0023] In certain other embodiments, the soluble compounds or moieties used to functionalize the first amino acid of Z include: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m 、8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m , where m is an integer from 0 to 10.

[0024] In certain embodiments, soluble compounds and moieties for functionalizing at least two Lys of Z include: Ado, Ado-Ado-(Lys) m 、8Ado、8Ado-8Ado-(Lys)m 、(Lys) m or (Pro-Lys) m . Wherein m is an integer from 0 to 10.

[0025] In specific embodiments, the C-terminus of the peptide is amine-modified or amidated.

[0026] In another embodiment, the amino acid sequence of the parent peptide or peptidomimetic sequence is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

[0027] According to another aspect, a pharmaceutical composition is provided, comprising an effective amount of at least one prodrug of the present invention and a pharmaceutically acceptable excipient or carrier. In certain other aspects, this specification provides a therapeutic composition comprising an effective amount of at least one prodrug peptide of the present invention and an effective amount of at least one other bioactive agent. In certain embodiments, the composition further comprises an excipient or carrier as described herein.

[0028] According to another aspect, the present disclosure provides a method for treating or preventing hypoglycemia or hypoglycemia-related conditions or diseases. The method comprises: administering an effective amount of a prodrug peptide of the present disclosure or a pharmaceutical composition of the present disclosure, wherein the prodrug peptide is effective for treating or preventing hypoglycemia or hypoglycemia-related conditions or diseases.

[0029] According to other aspects, the present disclosure provides a method for preparing a prodrug peptide or a salt thereof (e.g., a pharmaceutically acceptable salt thereof), wherein the prodrug peptide or a salt thereof has improved biological properties (e.g., at least one property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism) compared to a parent peptide or peptidomimetic. The method comprises: adding a prodrug moiety to a parent peptide or peptidomimetic (e.g., synthesizing the prodrug moiety and the parent peptide or peptidomimetic as a contiguous sequence by any method known or known to a person skilled in the art), wherein the prodrug moiety comprises ≥2 amino acids, which are cleaved in vivo to release the peptide or peptidomimetic.

[0030] In specific embodiments, the prodrug moiety is located at the amino terminus of the parent peptide or peptidomimetic. In other embodiments, the prodrug moiety is located at the carboxyl terminus of the parent peptide or peptidomimetic.

[0031] In some embodiments, the prodrug moiety has the following structure: (Glu-Pro) m or (Lys-Pro) X , where X is an integer ≥1.

[0032] In certain embodiments, at least the first Lys of the prodrug moiety is functionalized with a soluble compound.

[0033] In other embodiments, at least two Lys groups of the prodrug moiety are functionalized with a soluble compound.

[0034] In a specific embodiment, the prodrug moiety comprises two amino acids, wherein the first amino acid is functionalized with a soluble compound.

[0035] In other embodiments, the soluble compound is water soluble.

[0036] In one embodiment, the prodrug moiety is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.

[0037] In other embodiments, the first amino acid of the prodrug moiety is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m 、8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m . Wherein m is an integer from 0 to 10.

[0038] In some embodiments, at least two Lys of the prodrug moiety are functionalized with soluble compounds or moieties including: Ado, Ado-Ado-(Lys) m 、8Ado、8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m . Wherein m is an integer from 0 to 10.

[0039] In other embodiments, the amino acid sequence of the parent peptide or peptidomimetic is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

[0040] In other embodiments, the method further comprises amidating the C-terminus of the peptide.

[0041] In another embodiment, the method further comprises modifying the C-terminus of the protein with an amine.

[0042] The foregoing entire contents of the present invention are merely illustrative and do not limit the scope of the present disclosure and the appended claims. Based on the claims, description and examples of the present invention, those of ordinary skill in the art will recognize other objects and advantages related to the compositions, methods and processes of the present invention. For example, various aspects and embodiments of the present invention can be used in a variety of combinations, all of which are clearly contemplated by the present invention. These additional advantages, objects and embodiments are clearly within the scope of the present invention. Publications and other materials used to illustrate the background of the present invention and to provide additional details on application in special cases are incorporated herein by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] The accompanying drawings, which are incorporated in and constitute a part of the specification, show several embodiments of the present invention and, together with the description, serve to explain the principles of the present invention. The accompanying drawings are only for the purpose of illustrating embodiments of the present invention and should not be construed as limiting the present invention.

[0044] Figure 1 . Peptides 1-9 are shown and aligned, including the parent peptide and several exemplary prodrugs containing the parent peptide.

[0045] Figure 2 . An exemplary functionalization of Lys with Lys-Lys-Lys-Lys-Lys-Lys is shown, where when the Lys is at the N-terminus, one skilled in the art would understand that the hydrogen is bonded to the nitrogen on the left side of the chemical structure.

[0046] Figure 3 . An exemplary functionalization of Lys with 8Ado-8Ado is shown, where when K* is N-terminal, one skilled in the art would understand that the hydrogen is bonded to the nitrogen on the left side of the chemical structure.

[0047] Figure 4 . An exemplary functionalization of Lys with Ado-Ado is shown, where when K* is N-terminal, one skilled in the art would understand that the hydrogen is bonded to the nitrogen on the left side of the chemical structure.

[0048] Figure 5 . Stability of peptide 3 (1 mg / mL) in PBS (phosphate buffered saline) at room temperature for 10 days.

[0049] Figure 6 . Stability of peptide 4 (1 mg / mL) in water at room temperature for 46 days.

[0050] Figure 7 . Stability of peptide 4 (1 mg / mL) in physiological serum at room temperature for 18 days.

[0051] Figure 8. Stability of peptide 5 (1 mg / mL) in physiological serum at 4°C for 7 days.

[0052] Fig. 9 . Stability of peptide 5 (1 mg / mL) in physiological serum at room temperature for 18 days.

[0053] Fig.10 Blood glucose measurements (mg / dl) 30 minutes before administration and at t = 10, 20, 30, 45, 60 and 120 minutes after injection, *p < 0.05; **p < 0.01: two-way ANOVA with Bonferroni post hoc test.

[0054] Fig.11A .and Fig. 11B (A) shows and aligns peptides 10-25, which include a parent peptide and several exemplary prodrugs containing the parent peptide. (B) shows Fig.11A The chemical structure of the modified lysine shown in , where when K* is the N-terminus, those skilled in the art will understand that hydrogen is bound to the nitrogen on the left side of the chemical structure.

[0055] Fig.12 . Blood glucose (mg / dl) was measured 30 min before administration and at t=10, 20, 30, 45, 60 and 120 min after injection of Wistar rats administered with vehicle and compounds 10, 13, 14 and 19 (n=6), *p<0.05; **p<0.01: two-way ANOVA with Bonferroni post hoc test.

[0056] Fig.13 . Blood glucose measurements (mg / dl) before and after administration of vehicle and compounds 10, 19, 21 and 25 to Wistar rats and at t=2, 5, 30, 60 and 120 minutes after injection (n=3), *p<0.05; **p<0.01; ***p<0.001: two-way ANOVA with Bonferroni post hoc test.

[0057] Fig.14A and Fig. 14B (A) High performance liquid chromatography (HPLC) spectrum of peptide 10 (10-100%; CH3CN 0.1% trifluoroacetic acid (TFA) dissolved in H2O 0.1% TFA, 10 min, C18). (B) Liquid chromatography-mass spectrometry (LC-MS) spectrum of peptide 10.

[0058] Fig.15A and Fig. 15B(A) HPLC spectrum of peptide 11 (10-100%; CH3CN 0.1% TFA dissolved in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 11.

[0059] Fig.16A and Fig. 16B (A) HPLC spectrum of peptide 12 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 12.

[0060] Fig.17A and Fig. 17B (A) HPLC spectrum of peptide 13 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 13.

[0061] Fig.18A and Fig.18B (A) HPLC spectrum of peptide 14 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 14.

[0062] Fig.19A and Fig.19B (A) HPLC spectrum of peptide 15 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 15.

[0063] Fig. 20A and Fig. 20B (A) HPLC spectrum of peptide 16 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 16.

[0064] Fig.21A and Fig.21B (A) HPLC spectrum of peptide 17 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 17.

[0065] Fig.22A and Fig. 22B (A) HPLC spectrum of peptide 18 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 18.

[0066] Fig.23A and Fig. 23B (A) HPLC spectrum of peptide 19 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 19.

[0067] Fig.24A and Fig. 24B (A) HPLC spectrum of peptide 20 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 20.

[0068] Fig.25A and Fig.25B (A) HPLC spectrum of peptide 21 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 21.

[0069] Fig.26A and Fig.26B (A) HPLC spectrum of peptide 22 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 22.

[0070] Fig.27A and Fig.27B (A) HPLC spectrum of peptide 23 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 23.

[0071] Fig.28A and Fig.28B (A) HPLC spectrum of peptide 24 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 24.

[0072] Fig.29A and Fig.29B (A) HPLC spectrum of peptide 25 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 25. DETAILED DESCRIPTION

[0073] Provided below is a detailed description of the present invention to help those skilled in the art implement the present invention. Without departing from the spirit or scope of the present invention, those of ordinary skill in the art may modify and change the embodiments described herein. Although methods and materials similar to or equivalent to those described herein may also be used in the practice or testing of the present invention, preferred methods and materials are now described. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs. The terms used in this disclosure are only used to describe specific embodiments and are not intended to limit the present invention. All publications, patent applications, patents, drawings and other references mentioned herein are expressly incorporated by reference in their entirety.

[0074] Where a range of values ​​is provided, it is understood that each intervening value (to one-tenth of the unit of the lower limit) between the upper and lower limits of the range, and any other specified or intervening values ​​in the range, are included in the disclosure unless the context clearly indicates otherwise. The upper and lower limits of these smaller ranges that may independently be included in smaller ranges are also included in the disclosure, subject to any explicitly excluded limits in the stated range. Where the stated range includes one or both limits, ranges excluding either of those included limits are also included in the disclosure.

[0075] As used herein, unless otherwise specified, the following terms may have the following meanings assigned to them. However, it should be understood that other meanings known or understood by those skilled in the art to which the present disclosure belongs are also possible and within the scope of the present disclosure.

[0076] It must be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference to the grammatical object of the article (i.e., to one or more than one or at least one). For example, "an element" means one element or more than one element.

[0077] The term "about" used herein in connection with numerical values ​​or ranges reflects the fact that there is a certain degree of variation in the art due to practical and / or theoretical limitations, and this level of variation is recognized and tolerated in the art. For example, due to inherent differences in the way certain equipment operates and / or makes measurements, smaller variations may be tolerated. Based on the above, the phrase "about" is generally used to cover values ​​within the standard deviation or standard error.

[0078] The phrase "and / or" as used herein in the specification and claims should be understood to refer to "any one or both" of the elements so combined, i.e., elements that are present in combination in some cases and separately in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements so connected. In addition to the elements explicitly identified by "and / or", other elements may optionally be present, whether related or unrelated to those specifically identified elements. Thus, as a non-limiting example, when used in conjunction with an open language (e.g., "comprising"), reference to "A and / or B" may refer to only A (optionally including other elements in addition to B) in one embodiment; may refer to only B (optionally including other elements in addition to A) in another embodiment; may refer to both A and B (optionally including other elements) in yet another embodiment; and so on.

[0079] As used in the specification and claims herein, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when the items in the list are separated, "or" or "and / or" should be interpreted as inclusive, i.e., including at least one of multiple elements or element lists, but also including more than one, and (optionally) other unlisted items. Only terms that are clearly indicated in the opposite direction, such as "only one" or "just one", or when used in the claims, "consisting of..." will refer to only including one element in multiple elements or element lists. Usually, when there is an exclusive term (such as "any one", "one of them", "only one" or "just one") in front, the term "or" used in this article should only be interpreted as representing an exclusive selection (that is, "one or the other, but not both").

[0080] In the claims and the foregoing specification, all transitional phrases, such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like, shall be understood to be open ended, i.e., meaning including, but not limited to, as provided in Section 2111.03 of the U.S. Patent Office Manual of Patent Examining Procedures. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively.

[0081] As used in the specification and claims herein, when referring to a list of one or more elements, the phrase "at least one" is understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows that elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers may optionally be present, whether related to or unrelated to those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or equivalently, "at least one of A or B", or equivalently "at least one of A and / or B"), in one embodiment, may refer to at least one, optionally including more than one A, without B (and optionally including elements other than B); in another embodiment, may refer to at least one, optionally including more than one B, without A (and optionally including elements other than A); in yet another embodiment, may refer to at least one, optionally including more than one A, and at least one, optionally including more than one B (and optionally including other elements); and so on.

[0082] It should also be understood that, in certain methods described herein that include multiple steps or operations, the order of the steps or operations of the method is not necessarily limited to the order of the steps or operations of the method as described unless the context indicates otherwise.

[0083] The terms "co-administration" and "co-administering" or "combination therapy" refer to simultaneous administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a different time than administration of another or more therapeutic agents), as long as the therapeutic agents are present in the patient's body at the same time and in a dose, preferably an effective dose. In certain preferred aspects, one or more compounds of the invention described herein are co-administered in combination with at least one additional bioactive agent (e.g., an agent that stimulates glycogenolysis, stimulates gluconeogenesis, and / or inhibits glycogenogenesis). In particularly preferred aspects, co-administration of the compounds results in synergistic activity and / or therapy, including anti-hypoglycemic activity.

[0084] Unless otherwise indicated, the terms "compound", "peptide" and "peptidomimetic" as used herein refer to any specific compound disclosed herein, including its tautomers, regioisomers, geometric isomers, and, where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers), and, where applicable, pharmaceutically acceptable salts and derivatives thereof (including prodrug forms). Within its use in the context, the term compound generally refers to a single compound, but may also include other compounds, such as stereoisomers, regioisomers and / or optical isomers (including racemic mixtures) and specific enantiomers or enantiomerically enriched mixtures of the disclosed compounds. In the context, the term also refers to a prodrug form of a compound, which has been modified to facilitate administration of the compound and delivery to the active site. Note that in describing the compounds of the present invention, a number of substituents and variables associated therewith are described. It should be understood by those of ordinary skill in the art that the molecules described herein are stable compounds as generally described below.

[0085] The term "derivative" may refer to, but is not limited to, a chemical component (e.g., nucleic acid, nucleotide, polypeptide, or amino acid) formed directly, by modification, or by partial substitution from a natural compound. The term "analog" may refer to, but is not limited to, a chemical component (e.g., nucleic acid, nucleotide, polypeptide, or amino acid) having a structure similar to, but not identical to, a natural compound.

[0086] The term "effective amount / dose", "pharmaceutically effective amount / dose", "pharmaceutically effective amount / dose" or "therapeutically effective amount / dose" can be, but is not limited to, the amount / dose of the active ingredient of the pharmaceutical agent sufficient to prevent, inhibit the occurrence, improve, delay or treat (relieve the symptoms to some extent, preferably completely alleviate) at least one symptom of a condition, disorder or disease. The effective amount depends on the type of disease, the composition used, the route of administration, the type of mammal treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that will be considered by a person skilled in the medical field. Typically, 0.1 mg / kg to 1000 mg / kg body weight / day of the active ingredient is administered, depending on the potency of the agent. The toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell culture or experimental animals, for example, by determining the LD50 (the dose that kills 50% of the population) and the ED50 (the effective dose that treats 50% of the population). The dose ratio between toxicity and therapeutic effect is the therapeutic index, which can be expressed as the ratio of LD50 / ED50. Compounds that exhibit higher therapeutic indices are preferred. Although compounds that exhibit toxic side effects can be used, it should be noted that a delivery system that targets such compounds to the affected tissue site should be designed to minimize potential damage to uninfected cells, thereby reducing side effects. Data obtained from cell culture assays and animal studies can be used to formulate dosage ranges suitable for humans. The dosage of such compounds is preferably within the range of circulating concentrations, which includes an ED50 with little or no toxicity. Depending on the dosage form used and the route of administration used, the dosage can vary within this range. For any compound used in the method disclosed herein, the therapeutically effective dose can first be estimated from a cell culture assay. Dosages can be formulated in animal models to reach a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that reaches half the maximum inhibition of symptoms) determined in cell culture. Such information can be used to more accurately determine dosages useful to humans. The level in plasma can be measured, for example, by high performance liquid chromatography.

[0087] The terms "pharmacological composition", "therapeutic composition", "therapeutic preparation" or "pharmaceutically acceptable preparation" may be, but are in no way limited to, a composition or preparation that enables the agent provided by the present invention to be effectively distributed in a form suitable for administration to the physical location most suitable for its desired effect (e.g., systemic administration).

[0088] The term "pharmaceutically acceptable" or "pharmacologically acceptable" may refer to, but is in no way limited to, entities and compositions that do not produce adverse, allergic or other untoward reactions when properly administered to animals or humans.

[0089] The term "pharmaceutically acceptable carrier" or "pharmacologically acceptable carrier" can be, but is by no means limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with drug administration. Suitable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, a standard reference in this field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles, such as fixed oils, may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active compound, it is contemplated for use in the composition. Supplementary active compounds may also be incorporated into the composition.

[0090] The term "systemic administration" refers to administration routes such as enteral or parenteral administration, which result in systemic distribution of the agent, leading to systemic absorption of the drug or accumulation in the bloodstream and then distribution throughout the body. The appropriate form depends in part on its use or its route of entry, such as oral, transdermal or by injection. The form should not prevent the composition or formulation from reaching the target cells (i.e., the cells to which the negatively charged polymer is desired to be delivered). For example, a pharmacological composition injected into the bloodstream should be soluble. Other factors are known in the art and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect. Administration routes that lead to systemic absorption include, but are not limited to, intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. The rate at which a drug enters the blood circulation has been shown to be a function of molecular weight or size. The use of liposomes or other drug carriers containing the compounds of the present invention can potentially localize the drug, for example, in certain tissue types (e.g., tissues of the reticuloendothelial system (RES)). Liposomal formulations that can promote the binding of drugs to the surface of cells (such as lymphocytes and macrophages) are also useful.

[0091] The term "local administration" refers to an administration route that delivers the agent to the appropriate site of the lesion or disease or a site adjacent thereto (eg, within about 10 cm).

[0092] The term "conservative mutation" refers to a change, addition or deletion of a single amino acid or a small number of amino acids caused by substitution, deletion or addition of nucleic acid in a coding sequence, wherein the change of nucleic acid results in the substitution of chemically similar amino acids. Amino acids that can be conservatively substituted for each other include: basic: arginine (R), lysine (K), histidine (H); acidic: aspartic acid (D), glutamic acid (E), asparagine (N), glutamine (Q); hydrophilic: glycine (G), alanine (A), valine (V), leucine (L), isoleucine (I); hydrophobic: phenylalanine (F), tyrosine (Y), tryptophan (W); sulfur-containing: methionine (M), cysteine ​​(C). In addition, sequences that differ due to conservative variations are usually homologous.

[0093] "Homology" or "identity" refers to the nucleotide sequences of two or more nucleic acid molecules or two or more nucleic acid or amino acid sequences being partially or completely identical. In certain embodiments, the homologous nucleic acid or amino acid sequence has 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% sequence similarity or identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, respectively.

[0094] "Homologues" can exist naturally, or can be created by artificially synthesizing one or more nucleic acids (or the amino acids produced thereby) with related sequences, or by modifying one or more nucleic acids (or the amino acids produced thereby) to produce related nucleic acids. When nucleic acids are derived from a common ancestral sequence (e.g., an ortholog or a paralog) naturally or artificially, nucleic acids (and the amino acid sequences produced thereby) are homologous. If the homology between two nucleic acids is not clearly described, homology can be inferred by comparing the nucleic acids between two or more sequences (including amino acid sequences). If the sequence shows a certain degree of sequence similarity, for example, greater than about 30% at the primary amino acid structure level, it can be concluded that they have a common ancestor. For purposes of the present disclosure, nucleic acid sequences are homologous if they are similar enough to allow recombination and / or hybridization under low stringency conditions. Additionally, polypeptides are considered homologous if their nucleic acid sequences are sufficiently similar to allow recombination or hybridization under low stringency conditions, and optionally they exhibit similar activity as the parent peptide, and optionally they can be recognized by (i.e., cross-react with) antibodies specific for an epitope contained in the amino acid sequence of the parent peptide (e.g., at least one of SEQ ID NO: 1 or SEQ ID NO: 2).

[0095] The term "cell" may be, but is by no means limited to, its usual biological meaning, and does not refer to a whole multicellular organism. The cell may be, for example, in vivo, in vitro or ex vivo (e.g., in cell culture), or present in a multicellular organism, including, for example, birds, plants, and mammals (e.g., humans, cows, sheep, apes, monkeys, pigs, dogs, and cats). The cell may be prokaryotic (e.g., a bacterial cell) or eukaryotic (e.g., a mammalian or plant cell).

[0096] The term "host cell" may mean, but is in no way limited to, a cell that can be used to carry a heterologous nucleic acid or express a peptide or protein encoded by a heterologous nucleic acid. A host cell may contain genes that are not present in the cell in its native form (non-recombinant), genes that are present in the cell in its native form (wherein the genes are artificially modified and reintroduced into the cell), or endogenous nucleic acids of the cell that have been artificially modified without removing nucleic acids from the cell. The host cell may be eukaryotic or prokaryotic. General growth conditions necessary for bacterial culture may be referred to in literature such as BERGEY'S MANUAL OF SYSTEMATIC BACTERIOLOGY, Vol. 1, NR Krieg, ed., Williams and Wilkins, Baltimore / London (1984). A "host cell" may also be a host cell in which endogenous genes or promoters or both have been modified to produce one or more polypeptide components of the complex of the present invention.

[0097] The term "patient" or "subject" is used throughout the specification to describe an animal, preferably a human or domesticated animal, to which treatment, including prophylactic treatment, using a composition according to the present invention is provided. For the treatment of those infections, conditions or disease states that are specific to a particular animal (e.g., a human patient), the term "patient" refers to that particular animal, including domestic animals (e.g., dogs or cats) or farm animals (e.g., horses, cattle, sheep, etc.). Generally, in the present invention, the term "patient" refers to a human patient, unless otherwise indicated or implied in the context in which the term is used.

[0098] The term "therapeutically effective amount or dosage" includes a drug dosage that can achieve a therapeutic effect in a subject in need thereof. For example, a therapeutically effective amount of a drug can be an amount that can prevent or alleviate one or more symptoms associated with a disease or condition (e.g., tissue damage or a disease or condition associated with muscle). The exact amount can be determined by a person skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0099] A kit is any article (e.g., package or container) comprising at least one prodrug peptide described in the present disclosure or a pharmaceutical composition described in the present disclosure. The article can be promoted, distributed, or sold as a unit for performing the method of the present disclosure. In addition, the kit of the present disclosure may preferably include instructions describing its suitable method of administration. Such a kit can be conveniently used in, for example, a clinical setting to treat or improve patients showing symptoms of a disease or condition (e.g., hypoglycemia or a disease or condition associated with hypoglycemia).

[0100] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification, including definitions, will prevail. In addition, the materials, methods, and examples are illustrative only and not restrictive.

[0101] The following references provide the skilled artisan with general definitions of many of the terms used in the present invention, and the entire disclosures of these references are incorporated herein by reference: Singleton et al., Dictionary of Microbiology and Molecular Biology (2 nd ed.1994);The Cambridge Dictionary of Science and Technology(Walkered.,1988);The Glossary of Genetics,5 thEd., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, the Harper Collins Dictionary of Biology (1991).

[0102] The present specification provides therapeutic compositions and methods of using them, which are based on the surprising and unexpected discovery that chemically modified peptides or peptidomimetics as described herein have improved one or more biological properties. In particular, relative to the parent peptide or peptidomimetics (i.e., unmodified peptides), the prodrug peptides of the present disclosure include an improvement in at least one biological property (e.g., an improvement in a biological property that enhances its therapeutic effect). The modified peptides of the present disclosure (i.e., prodrug peptides) include a prodrug portion that is cleaved in vivo after administration to release the parent peptide or peptidomimetics.

[0103] Without being limited to any particular theory, it is hypothesized that the parent peptide or peptidomimetic is released from the prodrug form by dipeptidyl peptidase-4 (DPP4), also known as adenosine deaminase complex protein 2 or CD26 (cluster of differentiation 26). That is, DDP4 is believed to be a serine exopeptidase expressed on the surface of most cell types that cleaves the X-proline dipeptide from the N-terminus of the polypeptide and cleaves the prodrug moiety in vivo to release the parent peptide or peptidomimetic. However, it is possible that other one or more enzymes, either alone or in combination with DDP4, participate in or assist in the release of the parent peptide or peptidomimetic from the prodrug form.

[0104] Pharmacological peptides or peptidomimetics exhibit many favorable properties, making them excellent therapeutic agents, especially for autoimmune diseases. In addition to the fact that their synthesis and production can be highly optimized and in some cases very simple and automatable compared to some biologics, the peptides or peptidomimetics selected as active ingredients of pharmaceutical compositions are also characterized by their stability and durability, ease of handling, relatively low doses that must be administered to patients and their costs, which remain desirable relative to most biologics. Short peptides themselves are not immunogenic, which is another important advantage for treating patients with chronic autoimmune diseases (Schall and Muller, 2014).

[0105] The present invention provides therapeutic compositions and methods of using the compositions, which are based on the surprising and unexpected discovery that chemically modified peptides or peptidomimetics as described herein produce prodrugs with improved biological properties, which enhance the therapeutic effect of the parent peptide or peptidomimetics. In one aspect, the present disclosure provides a prodrug peptide or a salt thereof (e.g., a pharmaceutically acceptable salt thereof), wherein the prodrug peptide or a salt thereof has an improvement in at least one biological property compared to the parent peptide or peptidomimetics, wherein the biological property is selected from the group consisting of: therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism, and the prodrug peptide comprises the following structure:

[0106] Z n -pep,

[0107] Wherein, pep is a parent peptide or a peptidomimetic; Z is a prodrug portion, such as an amino acid sequence of n amino acids; wherein Z (the prodrug portion) is cleaved in vivo to release pep; and n is an integer number of amino acids ≥ 2 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more).

[0108] The prodrug moiety (Z) may have the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer ≥ 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more). For example, Z can be Glu-Pro, Lys-Pro, Glu-Pro-Glu-Pro (SEQ ID NO: 30), Lys-Pro-Lys-Pro (SEQ ID NO: 11), Glu-Pro-Glu-Pro-Glu-Pro (SEQ ID NO: 31), and Lys-Pro-Lys-Pro-Lys-Pro (SEQ ID NO: 12). In other embodiments, Z comprises 2 amino acids, and the first amino acid is functionalized with a soluble compound described herein. In any of the embodiments described herein, at least the first amino acid (e.g., Lys) of the prodrug moiety (e.g., the first amino acid, the third amino acid, the fifth amino acid, the seventh amino acid, or a combination thereof, e.g., the first and third amino acids (e.g., the first and second Lys); the first and fifth amino acids (e.g., the first and third Lys); the first, third, and fifth amino acids (e.g., the first, second, and third Lys); etc.) can be functionalized with a soluble compound. In specific embodiments, at least one (e.g., at least two, at least three, or at least four) Lys of Z is functionalized with a soluble compound described herein.

[0109] The soluble compound may be water soluble. For example, the prodrug moiety may be functionalized with a soluble compound including: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m 、8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m 、(Lys) m (e.g., [Lys]6; SEQ ID NO: 13) or (Pro-Lys) m(e.g., [Pro-Lys]3, SEQ ID NO: 29), wherein m is an integer from 0 to 10. In certain embodiments, at least 2 (e.g., at least 2, 3, or 4) Lys of Z are functionalized with a soluble compound, which may include: Ado, Ado-Ado-(Lys) m 、8Ado、8Ado-8Ado-(Lys) m 、(Lys) m (e.g., [Lys]6; SEQ ID NO: 13), or (Pro-Lys) m (e.g., [Pro-Lys]3, SEQ ID NO:29), wherein m is an integer from 0 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10).

[0110] The peptide may be C-terminally amine modified or the C-terminus of the peptide may be amidated.

[0111] The parent peptide or peptidomimetic can be any peptide or peptidomimetic that is desired to improve at least one biological property to improve the therapeutic effect of the peptide or peptidomimetic. For example, the amino acid sequence of the parent peptide or peptidomimetic can have at least 60% identity (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99% or 100% identity) with glucagon. In specific embodiments, the amino acid sequence of the parent peptide or peptidomimetic is at least 60% identical (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

[0112] According to another aspect, a pharmaceutical composition is provided, which comprises at least one prodrug peptide described in the present disclosure, and a pharmaceutically acceptable excipient or carrier. In certain other aspects, the present disclosure provides a therapeutic composition, which comprises at least one prodrug peptide described in the present invention and at least one other bioactive agent. For example, when the parent peptide is glucagon or its peptidomimetic, the other bioactive agent can be any agent that stimulates glycogenolysis, stimulates gluconeogenesis and / or inhibits glycogenogenesis. In certain embodiments, the composition also comprises an excipient (e.g., a pharmaceutically acceptable excipient) or a carrier (e.g., a pharmaceutically acceptable carrier) as described herein.

[0113] According to another aspect, the present disclosure provides a method for treating or preventing hypoglycemia or a condition or disease associated with hypoglycemia. The method comprises administering an effective amount of a prodrug peptide of the present invention or a pharmaceutical composition of the present invention, wherein the prodrug peptide comprises a parent peptide or peptidomimetic, the amino acid sequence of the parent peptide or peptidomimetic having at least 60% identity to glucagon (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99% or 100% identity). For example, the peptide or peptidomimetic can comprise an amino acid sequence that is at least 60% identical (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and the prodrug can be effective in treating or preventing hypoglycemia or a condition or disease associated with hypoglycemia.

[0114] According to another aspect, the present disclosure provides a method for preparing a prodrug peptide or a salt thereof (e.g., a pharmaceutically acceptable salt thereof), wherein the prodrug peptide or a salt thereof has improved biological properties (e.g., at least one property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism) compared to a parent peptide or peptidomimetic. The method comprises: adding a prodrug moiety to a parent peptide or peptidomimetic (e.g., synthesizing the prodrug peptide by solid phase synthesis or liquid phase synthesis, wherein the prodrug moiety is located at the amino terminus or carboxyl terminus of the parent peptide or peptidomimetic), wherein the prodrug moiety comprises ≥2 amino acids, which are cleaved in vivo to release the peptide or peptidomimetic.

[0115] In certain embodiments, the prodrug moiety has the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer and X ≥ 1 (e.g., X is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or greater). For example, the prodrug moiety can be selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP and KPKPKP.

[0116] In some embodiments, at least the first Lys of the prodrug moiety is functionalized with a soluble compound or moiety. In other embodiments, at least two Lys of the prodrug moiety are functionalized with soluble compounds or moieties. In a specific embodiment, the prodrug moiety comprises two amino acids, wherein the first amino acid is functionalized with a soluble compound or moiety. The soluble compound or moiety can be hydrophilic or soluble in aqueous solution.

[0117] In any embodiment, the first amino acid or the first Lys of the prodrug moiety can be functionalized with the following soluble compounds or moieties, including: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m . Wherein m is an integer from 0 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). For example, at least 2 Lys of the prodrug moiety are functionalized with the following soluble compounds, which include: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).

[0118] Those skilled in the art will appreciate that the parent peptide or peptidomimetic can be any peptide or peptidomimetic with therapeutic activity / effect. That is, the prodrug moiety (Z) disclosed herein can be utilized at the amino or carboxyl terminus of any peptide or peptidomimetic used for treatment, thereby improving at least one biological property of the peptide or peptidomimetic selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism.

[0119] For example, the parent peptide or peptidomimetic can have an amino acid sequence that is at least 85% identical (e.g., about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

[0120] The method may further include amidating the C-terminus of the peptide or modifying the C-terminus of the protein with an amine.

[0121] In any aspect or embodiment described herein, the peptides provided by the present disclosure can exist in the form of salts known to those skilled in the art, such as sodium salts, ammonium salts, calcium salts, magnesium salts, potassium salts, acetates, carbonates, citrates, chlorides, sulfates, aminochlorates, borates, benzenesulfonates, phosphates, dihydrogen phosphates, succinates, citrates, tartrates, lactates, mandelates, methanesulfonates (mesylate) or p-toluenesulfonates (toluenesulfonates). This list is provided as an example and is not meant to limit the present invention. For example, the technician can easily determine suitable salts according to his knowledge.

[0122] Chemical synthesis can be performed by any method deemed effective by those skilled in the art to synthesize the prodrug peptides described herein. For example, the prodrug peptides can be polymerized by adding the desired amino acids or molecules. One method is disclosed in the Examples section.

[0123] Pharmaceutical composition

[0124] On the other hand, the present invention provides compositions comprising an effective amount of one or more peptides described herein and an excipient or carrier. Therefore, in another embodiment, the present specification also provides a pharmaceutical composition comprising at least one prodrug peptide described herein or a combination product as described above, and also comprising a pharmaceutically acceptable carrier.

[0125] The prodrug peptides described herein (also referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise a peptide and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delaying agents, etc., that are compatible with drug administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active compound, it is contemplated for use in the composition. Supplementary active compounds (e.g., additional bioactive agents) may also be incorporated into the composition.

[0126] This specification provides a method for preparing a pharmaceutical composition. Such a method includes preparing a pharmaceutically acceptable carrier with at least one prodrug peptide as described herein. Such a composition may further include an additional active agent as described above. Therefore, the present invention further includes a method for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with at least one prodrug peptide as described herein (e.g., 1, 2, 3, 4, or 5) and one or more other active compounds (e.g., 1, 2, 3, 4, or 5).

[0127] The pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral administration (e.g., intravenous), intradermal, subcutaneous, oral, nasal (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous administration may include the following ingredients: sterile diluents (e.g., water for injection, saline, fixed oil, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents); antibacterial agents (e.g., benzyl alcohol); antioxidants (e.g., ascorbic acid or sodium bisulfate); chelating agents (e.g., ethylenediaminetetraacetic acid); buffers (e.g., acetate, citrate, or phosphate), and agents (e.g., sodium chloride or glucose) for adjusting tension. pH may be adjusted with acid or alkali (e.g., hydrochloric acid or sodium hydroxide). Parenteral preparations may be loaded into ampoules, disposable syringes, or multiple-dose vials made of glass or plastic.

[0128] Pharmaceutical compositions suitable for injection purposes include sterile aqueous solutions (in the case of water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injection solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, antibacterial water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should flow to the extent that it is easy to inject. It must remain stable under production and storage conditions and must be preservative-treated to prevent contamination by microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium, including, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion and by using a surfactant. The action of microorganisms can be prevented by various antibacterial and antifungal agents (such as chlorobutanol, phenol, ascorbic acid, etc.). In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

[0129] Sterile injection solutions can be prepared by incorporating the required amount of active compound (e.g., prodrug peptide) with the required combination of one or more ingredients listed above into a suitable solvent and then filtering and sterilizing. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and then incorporating the other ingredients required above. In the case of preparing sterile powders for the preparation of sterile injection solutions, preferred preparation methods are vacuum drying and freeze drying, which produce powders of the active ingredient and any other desired ingredients from a previously sterile filtered solution.

[0130] Oral compositions generally include an inert diluent or edible carrier. They can be placed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be combined with an excipient and used in the form of tablets, lozenges or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is orally administered and gargled, spit out or swallowed.

[0131] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0132] Systemic administration can also be carried out by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are well known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be accomplished by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gel or emulsion as commonly known in the art.

[0133] The compounds may also be prepared in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0134] In one embodiment, the active compound is prepared with a carrier that will protect the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microcapsule delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. The preparation methods of such preparations are obvious to those skilled in the art. The materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes in which monoclonal antibodies are incorporated) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0135] It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrete units suited as single dosages for subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the present invention is directly determined by the unique characteristics of the active compound and the specific therapeutic effect to be achieved, and the limitations inherent in the art of formulating such active compounds for individual treatment.

[0136] In certain embodiments of the methods provided herein, the method comprises the step of administering a therapeutic or pharmaceutical composition described herein at a dose of about 100 ng to about 5 mg. In some embodiments, for example in humans, the pharmaceutical composition described herein may comprise mannitol as a carrier, and the composition is administered in a single administration in the form of 10 μg to 500 μg, preferably 200 μg.

[0137] In certain other aspects, the dosage regimen can be repeated 1 to 3 times / week, weekly to once every four weeks, for several years, as needed for the therapeutic window. In a preferred embodiment, the dosage regimen is once every 4 weeks, but can be repeated twice a year for several years. An example of administration is: an injection of 200 μg of peptide once every 4 weeks for 12 weeks (i.e., 3 injections, 4 weeks apart). Treatment is extended by administration every 6 months.

[0138] Preferred pharmaceutically acceptable carriers can include, for example, xanthan gum, locust bean gum, galactose, other sugars, oligosaccharides and / or polysaccharides, starch, starch fragments, dextrin, British gum (British gum) and mixtures thereof. Advantageously, pharmaceutically acceptable carriers are of natural origin. Pharmaceutically acceptable carriers can be or can further include an inert sugar diluent selected from monosaccharides or disaccharides. Advantageous sugar is mannitol.

[0139] Advantageously, the invention relates to a pharmaceutical composition as defined above, in the form of liposomes or nanoparticles, or in the form of a solution. An advantageous solution is one comprising 1-15%, in particular about 10%, of mannitol. The solution should be isotonic.

[0140] The invention also relates to a medicament comprising a combination as defined above for simultaneous, separate or sequential use.

[0141] Treatment

[0142] On the other hand, the present disclosure provides a method for treating, preventing and / or improving the symptoms of hypoglycemia or hypoglycemia-related diseases or conditions. The method includes administering an effective amount of a prodrug peptide of the present disclosure or a medicament or therapeutic composition of the present disclosure to a subject in need thereof, wherein the composition is effective for treating, preventing and / or improving at least one symptom of hypoglycemia or hypoglycemia-related diseases or conditions. In certain embodiments, the disease or condition is insulin-induced hypoglycemia.

[0143] The present disclosure also provides a prodrug peptide comprising a peptide or peptidomimetic as described herein and a prodrug moiety as described herein for use as a medicament, particularly for the treatment of hypoglycemia or a disease or condition associated with hypoglycemia.

[0144] Those skilled in the art will appreciate that there are many methods for preparing the prodrug peptides or peptidomimetics disclosed herein. For example, standard Fmoc / Boc protected solid phase peptide synthesis can be utilized. Thus, when the amine on the lysine side chain is functionalized, then the Fmoc / Boc protecting group of the amine of the N-terminal lysine can be switched if it is the last amino acid, or if Alloc lysine is used, if the lysine is not the last amino acid and the Boc is located at the N-terminus of the last amino acid. The Alloc at the end of the sequence is then removed with Pd(o), and the amine is functionalized.

[0145] Example

[0146] Example 1

[0147] General procedure for peptide synthesis. The synthesis of peptides 1-9 corresponding to SEQ ID NOs: 2-5, 8-10, 6 and 7, respectively, was carried out on a LibertyBlue automated peptide synthesizer from CEM using a Fmoc solid phase strategy with PyBop and DIEA as coupling reagents according to previously reported procedures. Merrifield, RBJ Am. Chem. Soc. 1963, 85, 2149–2154; Palasek SA, Cox ZJ, Collins JMJ Pept. Sci. 2007; 13, 143–148; Douat-Casassus C, Pulka K, Claudon P, Guichard G, Org. Lett. 2012, 14, 3130–3133.

[0148] Solubility analysis of exemplary peptides. Prepare a peptide or peptidomimetic (glucagon or its analog) solution at a concentration of 3 mg / mL in 0.01 M HCl solution. Then dilute 0.1 mL of the stock solution to 1 mL with HCl (0.01 M), and measure its UV absorbance (to 280 nm) using a nanodrop UV spectrometer (NanoDrop 1000, purchased from Thermo Fisher). Adjust the pH of the remaining stock solution to pH 7 with Na2HPO4 (0.1 M) and place it at 4°C overnight. Centrifuge the solution three times (5 min, 4000 min- 1 ), take 0.1 mL of the supernatant and dilute to 1 mL with HCl (0.01 M). Measure the final UV absorbance.

[0149] The solubility was calculated by the following formula:

[0150] (Final absorbance / initial absorbance) x 3 mg / mL = solubility (mg / mL).

[0151] Table 1. Solubility and stability of peptides 1-7

[0152]

[0153] Stability analysis of exemplary peptides. A 1 mg / mL solution of the peptide or peptidomimetic (glucagon or its analog) was prepared in water or physiological serum and stored at room temperature or 4°C. The samples were analyzed by high performance liquid chromatography (HPLC) in 10 minutes with a gradient from 10% to 100% CH3CN (+0.1% trifluoroacetic acid (TFA) v / v) / water (+0.1% TFA v / v). The HPLC column (EC 100 / 4NUCLEODUR 100-3C18ec) was purchased from Macherey-Nagel.

[0154] Peptides 3, 4, and 5 showed good stability after long-term storage at room temperature. Figure 5-7 and 9, in water, PBS, and physiological serum.

[0155] Exemplary in vivo analysis of glucagon-based peptides. During the whole experiment, 18 animals (rats, male, 8 weeks old) were kept in ventilated enriched cages (310 x 125 x 127 mm 3 ). They were housed in groups of 3 animals during the study, with a normal 12-hour light cycle (lights off at 08:00 p.m.), a temperature of 22±2°C, and a relative humidity of 50±10%. After 5 days of standard diet and tap water, animals were fasted for 3 hours and treated with glucagon and its analogs 3, 4, and 5 (10 nM / kg) by intravenous injection. Blood glucose was measured before dosing and at 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, and 120 minutes.

[0156] The exemplary peptides demonstrated a greater ability to increase blood glucose during the treatment period compared to the glucagon control, the inactive peptide, and the vehicle control.

[0157] Example 2

[0158] Detailed procedures for peptide synthesis.

[0159] A1: Rink amide (≈200 mg, loaded 0.5 mmol / g) or Sieber resin (≈160 mg, loaded 0.62 mmol / g) was swollen in dimethylformaldehyde (DMF; 3 mL) for 30 minutes. Then, an automatic peptide synthesizer (Liberty Blue from CEM) was used according to the previously reported procedures (Merrifield, RBJAm. Chem. Soc. 1963, 85, 2149–2154; Palasek SA, Cox ZJ, Collins JMJPept. Sci. 2007; 13, 143–148), using the Fmoc solid phase strategy, with PyBop (5 eq. relative to the resin loading) and N, N-diisopropylethylamine (DIEA; 10 eq. relative to the resin loading) as coupling reagents for peptide synthesis.

[0160] A2: Wang resin (≈220 mg, loading 0.4 mmol / g) was swollen in DMF (3 mL) for 30 min. The first amino acid (5 eq.) was dissolved in dry dichloromethane (DCM; 3 mL) under an inert atmosphere. N,N'-dicyclohexylcarbodiimide (DCC; 2.5 eq.) was added and the mixture was stirred at 0°C for 20 min, then the DCM was concentrated and DMF was added. The mixture was loaded onto the swollen Wang resin with a small amount of 4-dimethylaminopyridine (DMAP). After the resin was stored at room temperature for 2 h, it was filtered and washed 3 times with DMF, DCM and MeOH. The peptide was then synthesized according to step A1 or A2.

[0161] B: Alloc deprotection: The resin was swelled in DCM for 30 minutes, then Pd(Ph3)4 (0.25 eq.) and phenylsilane (10 eq.) were added. The mixture was stirred at room temperature for 45 minutes, then the resin was filtered and washed 3 times with DCM.

[0162] Lysis procedure:

[0163] C1: After the synthesis is complete, the resin is transferred to a syringe with a frit and washed 3 times with DMF, 3 times with CH2Cl2, and 3 times with Et2O. The resin is cleaved from the resin using 88% TFA (3 mL) containing 2% triisopropylsilane, 5% phenol, and 5% water. After 2 hours, the resin is filtered and discarded. Diethyl ether is added to precipitate the oligomer, and the solid is ground and filtered.

[0164] C2: After the synthesis is complete, the resin is transferred to a syringe with a filter cartridge and washed 3 times with DMF, 3 times with CH2Cl2, and 3 times with Et2O. The resin is cleaved using 88% TFA (3 mL) containing 2.5% triisopropylsilane and 2.5% water. After 2 hours, the resin is filtered and discarded. Diethyl ether is added to precipitate the oligomer, and the solid is ground and filtered.

[0165] General purification procedures. All peptides were purified by semi-preparative HPLC, the instrument used was Dionex U3000SD, the chromatographic column used was Macherey-Nagel Nucleodur C18ec chromatographic column (10x250mm, 5μm), the flow rate was 4mL / min, and the UV detection wavelength was 200nm. The mobile phase consisted of 0.1% (v / v) TFA-H2O (solvent A) and 0.1% (v / v) TFA-CH3CN (solvent B).

[0166] General Analytical Procedures. Peptides 10-25, corresponding to SEQ ID NO: 1 and 14-28, respectively, were analyzed by analytical RP-HPLC, the instrument used was Dionex U3000SD, the chromatographic column used was Macherey-Nagel Nucleodur C18ec chromatographic column (4x 100mm, 3μm), the flow rate was 1mL / min, and the UV detection wavelength was 200nm. The mobile phase consisted of 0.1% (v / v) TFA-H2O (solvent A) and 0.1% (v / v) TFA-CH3CN (solvent B). Liquid chromatography-mass spectrometry (LC-MS) analysis was performed on an ultra-high performance liquid chromatography (UHPLC; Agilent 1290Infinity) coupled to an electrospray ionization time-of-flight (ESI-TOF) mass spectrometer (Agilent 6230ESI).

[0167] Solubility analysis. A solution of the compound (e.g., glucagon or its analog) is prepared in a 0.01M HCl solution. 0.1 mL of the stock solution is then diluted to 1 mL with HCl (0.01M), and the UV absorbance (to 280 nm) is measured using a NanoDrop UV spectrometer (NanoDrop1000, purchased from Thermo Fischer). The pH of the remaining stock solution is adjusted to pH 7 using Na2HPO4 (0.1M), and the solution is allowed to stand overnight at 4°C. The solution is then centrifuged 3 times (5 min, 4000 min -1 ), take 0.1 mL of the supernatant and dilute to 1 mL with HCl solution (0.01 M). Measure the final UV absorbance. The solubility can be obtained by the following formula:

[0168] (Final absorbance / initial absorbance) x 100 = solubility percentage

[0169] The solubility percentages of glucagon and exemplary peptides are shown in Table 2. As shown in Table 2, the exemplary glucagon analogs have higher solubility than glucagon.

[0170] Table 2. Solubility of glucagon and its analogs in PBS buffer (0.1 M, pH 7.4)

[0171]

[0172] Stability analysis. A solution of peptide or peptidomimetic (glucagon and its analogs) at a concentration of 1 mg / mL was prepared in a 0.9% NaCl aqueous solution and stored at room temperature, 4°C, 37°C and or 50°C. The samples were analyzed by RP-HPLC, the instrument used was Dionex U3000SD, the chromatographic column used was Macherey-Nagel Nucleodur C18ec chromatographic column (4x 100mm, 3μm), the flow rate was 1mL / min, and the UV detection wavelength was 200nm. The mobile phase consisted of 0.1% (v / v) TFA-H2O (solvent A) and 0.1% (v / v) TFA-CH3CN (solvent B). After incubation at different temperatures for different times, the percentages of the remaining exemplary peptides and glucagon are shown in Table 3.

[0173] Table 3. Percentage of peptides remaining in 0.9% NaCl aqueous solution after incubation at different temperatures for different times (T0 = 100%)

[0174]

[0175]

[0176] Rat experiments. Rats (Wistar rats, male, 8 weeks old, n = 6 or 3) were housed in ventilated enriched cages (310 x 125 x 127 mm) throughout the experiment. 3 ). During the experiment, the animals were grouped and housed, with 3 animals in each group, under a regular 12-hour light cycle (lights turned off at 08:00 p.m.), a temperature of 22±2°C, and a relative humidity of 50±10%. After 5 days of adaptation to standard diet and tap water, the animals were fasted for 3 hours and glucagon (10) and its analogs 13, 14, 19, 21, and 25 (10 nM / kg) were administered intravenously. Blood glucose was measured before and after administration at different times, as shown in Table 1. Fig.12 and 13 As shown. Fig.12 and13 As shown, compared with glucagon, glucagon analogs can break down glycogen more efficiently, which is manifested by increased blood glucose levels in rats.

[0177] Peptide characterization

[0178] Peptide 10:

[0179] HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH

[0180] Peptide 10 was synthesized starting from Wang resin (196 mg, 0.1 mmol) using general procedure A2 and cleaved using procedure C2. The final product 10 was purified by semi-preparative HPLC. Yield 1.88 mg (yield 0.54%). HPLC: R t =5.03 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3482.40): 697.48 [M+5H] 5+ ,871.36[M+4H] 4+ ,1161.82[M+3H] 3+ .

[0181] Peptide 11:

[0182] HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2

[0183] Peptide 11 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C2. The final product 11 was purified by semi-preparative HPLC. Yield 1.59 mg (yield 0.45%). HPLC: R t =5.03 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3481.75): 697.35 [M+5H] 5+ ,871.44[M+4H] 4+ ,1161.59[M+3H] 3+ .

[0184] Peptide 12:

[0185] KPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2

[0186] Peptide 12 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 12 was purified by semi-preparative HPLC. Yield 9.26 mg (yield 2.50%). HPLC: R t =5.06 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3688.65): 615.77 [M+6H] 6+ 738.73[M+5H] 5+ ,923.17[M+4H] 4+ ,1230.57[M+3H] 3+ .

[0187] Peptide 13:

[0188] KPKPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2

[0189] Peptide 13 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 13 was purified by semi-preparative HPLC. Yield 16.0 mg (yield 4.1%). HPLC: R t =5.06 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3914.15): 653.36 [M+6H] 6+ 783.83[M+5H] 5+ ,979.53[M+4H] 4+ .

[0190] Peptide 14:

[0191] KPKPKPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2

[0192] Peptide 14 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 14 was purified by semi-preparative HPLC. Yield 8.0 mg (yield 1.9%). HPLC: R t =4.91 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4138.20): 592.16 [M+7H]7+ 690.7[M+6H] 6+ 828.66[M+5H] 5+ ,1035.60[M+4H] 4+ .

[0193] Peptide 15:

[0194] KPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2

[0195] Peptide 15 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C2. The final product 15 was purified by semi-preparative HPLC. Yield 2.86 mg (yield 0.77%). HPLC: R t =5.01 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3706.93): 618.82 [M+6H] 6+ 742.39[M+5H] 5+ ,927.73[M+4H] 4+ .

[0196] Peptide 16:

[0197] KPKPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2

[0198] Peptide 16 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C2. The final product 16 was purified by semi-preparative HPLC. Yield 6.48 mg (yield 1.6%). HPLC: R t =4.94 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3932.1): 656.35 [M+6H] 6+ 787.42[M+5H] 5+ ,984.02[M+4H] 4+ .

[0199] Peptide 17:

[0200] KPKPKPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2

[0201] Peptide 17 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C2. The final product 17 was purified by semi-preparative HPLC. Yield 7.99 mg (yield 1.9%). HPLC: R t =4.93 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4157.22): 594.89 [M+7H] 7+ 693.87[M+6H] 6+ 832.45[M+5H] 5+ ,1040.31[M+4H] 4+ .

[0202] Peptide 18:

[0203] EPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2

[0204] Peptide 18 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 18 was purified by semi-preparative HPLC. Yield 8.07 mg (yield 2.2%). HPLC: R t =5.04 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3689.19): 738.8 [M+5H] 5+ ,923.27[M+4H] 4+ ,1230.73[M+3H] 3+ .

[0205] Peptide 19:

[0206] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2,

[0207] Wherein K* represents lysine modified by KKKKKK.

[0208] Peptide 19 was synthesized starting from Sieber resin (160 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 19 was purified by semi-preparative HPLC. Yield 17.15 mg (yield 3.8%). HPLC: R t=4.62 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4457.46): 637.78 [M+7H] 7+ ,743.91[M+6H] 6+ ,892.49[M+5H] 5+ ,1115.36[M+4H] 4+ .

[0209] Peptide 20:

[0210] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2,

[0211] Wherein K* represents lysine modified by KKKKKK.

[0212] Peptide 20 was synthesized starting from Rink resin (227 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C2. The final product 20 was purified by semi-preparative HPLC. Yield 1.9 mg (yield 0.4%). HPLC: R t =4.54 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4476.18): 560.54 [M+8H] 8+ ,640.46[M+7H] 7+ ,747.03[M+6H] 6+ ,896.22[M+5H] 5+ ,1120.00[M+4H] 4+ .

[0213] Peptide 21:

[0214] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH,

[0215] Wherein K* represents that the lysine is modified by KKKKKK.

[0216] Peptide 21 was synthesized starting from Wang resin (227 mg, 0.1 mmol) using general procedure A2 and cleaved using procedure C2. The final product 21 was purified by semi-preparative HPLC. Yield 28.11 mg (yield 6.3%). HPLC: R t=4.63min (10-100%; CH3CN 0.1%TFA dissolved in H2O (0.1%TFA), 10min, C18); LC-MS (m / z 4477.14): 640.36[M+7H] 7+ ,746.93[M+6H] 6+ ,896.14[M+5H] 5+ ,1119.93[M+4H] 4+ .

[0217] Peptide 22:

[0218] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2,

[0219] Where K* represents lysine modified by 8Ado8Ado.

[0220] Peptide 22 was synthesized starting from Sieber resin (227 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 22 was purified by semi-preparative HPLC. Yield 1.9 mg (yield 0.4%). HPLC: R t =4.96 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 3978.06): 644.01 [M+6H] 6+ ,796.63[M+5H] 5+ ,995.57[M+4H] 4+ ,1326.79[M+3H] 3+ .

[0221] Peptide 23:

[0222] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2,

[0223] Wherein K* represents lysine modified by KKKKKK8Ado8Ado.

[0224] Peptide 23 was synthesized starting from Sieber resin (227 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C1. The final product 23 was purified by semi-preparative HPLC. Yield 11.99 mg (yield 2.5%). HPLC: R t=4.78 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4748.44): 594.30 [M+8H] 8+ ,679.07[M+7H] 7+ ,792.09[M+5H] 5+ ,950.3[M+4H] 4+ .

[0225] Peptide 24:

[0226] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2,

[0227] Where K* represents lysine modified by KPKPKP.

[0228] Peptide 24 was synthesized starting from Rink resin (227 mg, 0.1 mmol) using general procedure A1 and cleaved using procedure C2. The final product 24 was purified by semi-preparative HPLC. Yield 5.0 mg (yield 1.1%). HPLC: R t =4.91 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4382.98): 627.17 [M+7H] 7+ ,731.58[M+6H] 6+ ,877.58[M+5H] 5+ ,1096.75[M+4H] 4+ .

[0229] Peptide 25:

[0230] K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH,

[0231] Where K* represents lysine modified by KPKPKP.

[0232] Peptide 25 was synthesized starting from Wang resin (216 mg, 0.1 mmol) using general procedure A2 and cleaved using procedure C2. The final product 25 was purified by semi-preparative HPLC. Yield 7.02 mg (yield 1.6%). HPLC: R t =4.86 min (10-100%; CH3CN 0.1% TFA in H2O (0.1% TFA), 10 min, C18); LC-MS (m / z 4383.96): 627.14 [M+7H]7+ ,731.50[M+6H] 6+ ,877.60[M+5H] 5+ ,1096.76[M+4H] 4+ .

[0233] Specific implementation plan

[0234] According to one aspect, the present disclosure provides a prodrug peptide or a salt thereof having at least one improved biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism, wherein the prodrug peptide comprises the following structure: Z n -pep, wherein: pep is a parent peptide or peptidomimetic; Z is a sequence of n amino acids, wherein Z is cleaved in vivo to release pep, and n is an integer ≥2 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more).

[0235] In certain aspects or embodiments described herein, Z has the structure: (Glu-Pro) m or (Lys-Pro) X , where X is an integer ≥ 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).

[0236] In certain aspects or embodiments described herein, Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.

[0237] In certain aspects or embodiments described herein, at least the first Lys of Z is functionalized with a soluble compound.

[0238] In a certain aspect or embodiment described herein, at least two Lys groups of Z are functionalized with a soluble compound.

[0239] In a certain aspect or embodiment described herein, Z comprises 2 amino acids and the first amino acid is functionalized with a soluble compound.

[0240] In certain aspects or embodiments described herein, the soluble compound is water soluble.

[0241] In certain aspects or embodiments described herein, the first amino acid of Z is functionalized with a soluble compound or moiety such as 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m 、8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys)m , where m is an integer from 0 to 10.

[0242] In certain aspects or embodiments described herein, at least two Lys of Z are functionalized with a soluble compound or moiety such as Ado, Ado-Ado-(Lys) m 、8Ado、8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m . Wherein m is an integer from 0 to 10.

[0243] In certain aspects or embodiments described herein, the C-terminus of the peptide is amine-modified or amidated.

[0244] In certain aspects or embodiments described herein, the parent peptide or peptidomimetic has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

[0245] According to another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of the prodrug of the present invention and a pharmaceutically acceptable excipient or carrier.

[0246] According to another aspect, the present invention provides a method for treating or preventing hypoglycemia or hypoglycemia-related conditions or diseases. The method comprises: administering an effective amount of the prodrug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the prodrug peptide is effective for treating or preventing hypoglycemia or hypoglycemia-related conditions or diseases.

[0247] According to another aspect, the present disclosure provides a method for preparing a prodrug peptide or a salt thereof, wherein the prodrug peptide or a salt thereof has an improvement in at least one biological property compared to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The method comprises: adding a prodrug moiety to a parent peptide or peptidomimetic, wherein the prodrug moiety comprises ≥2 amino acids, which are cleaved in vivo to release the parent peptide or peptidomimetic.

[0248] In certain aspects or embodiments described herein, the prodrug moiety has the following structure: (Glu-Pro) m or (Lys-Pro) X , where X ≥ 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or greater).

[0249] In certain aspects or embodiments described herein, the prodrug moiety is selected from the group consisting of the following polypeptides: EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.

[0250] In a certain aspect or embodiment described herein, at least the first Lys of the prodrug moiety is functionalized with a soluble compound or moiety.

[0251] In a certain aspect or embodiment described herein, at least two Lys of the prodrug moiety are functionalized with a soluble compound or moiety.

[0252] In a certain aspect or embodiment described herein, the prodrug moiety comprises 2 amino acids, and the first amino acid thereof is functionalized with a soluble compound or moiety.

[0253] In certain aspects or embodiments described herein, the soluble compound is hydrophilic (ie, soluble in aqueous solution).

[0254] In certain aspects or embodiments described herein, the first amino acid of the prodrug moiety is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m 、8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m . Wherein m is an integer from 0 to 10.

[0255] In certain aspects or embodiments described herein, at least two Lys of the prodrug moiety are functionalized with the following soluble compounds or moieties, which include: Ado, Ado-Ado-(Lys) m 、8Ado、8Ado-8Ado-(Lys) m 、(Lys) m or (Pro-Lys) m , where m is an integer from 0 to 10.

[0256] In certain aspects or embodiments described herein, the C-terminus of the peptide is amine-modified or amidated.

[0257] In certain aspects or embodiments described herein, the parent peptide or peptidomimetic has an amino acid sequence at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

[0258] In certain aspects or embodiments described herein, the peptide or peptidomimetic comprises or is a peptide selected from SEQ ID NOs: 3-10 and 11-25.

[0259] In certain aspects or embodiments described herein, the peptide or peptidomimetic comprises or is a peptide selected from SEQ ID NOs: 2-9 and 11-25.

[0260] Although preferred embodiments of the present invention have been shown and described herein, it should be understood that such embodiments are provided by way of example only. Without departing from the spirit of the present invention, those skilled in the art will appreciate many variations, changes and substitutions. Therefore, the appended claims should encompass all such variations that fall within the spirit and scope of the present invention.

[0261] The contents of all references, patents, pending patent applications, and published patents cited in this application are hereby expressly incorporated by reference.

[0262] Those skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the invention described herein using only routine experiments. These equivalents should be covered by the appended claims. It should be understood that the detailed embodiments and embodiments described herein are given by way of example only, for illustrative purposes only, and should never be interpreted as limitations of the invention. Those skilled in the art will be inspired by this and will propose various modifications or changes, which are included in the spirit and scope of the present application and are considered within the scope of the appended claims. For example, the relative amounts of the ingredients can be changed to optimize the desired effects, additional ingredients can be added, and / or one or more of the described ingredients can be replaced with similar ingredients. According to the appended claims, other advantageous features and functions associated with the systems, methods and processes of the present invention will be apparent. In addition, those skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the invention described herein using only routine experiments. These equivalents should be covered by the appended claims. Sequence Listing <110> Ureka Ltd. Robert Zimmer Sebastian Goudreau <120> Prodrug peptides with improved pharmacological properties <130> 1513195.131WO2 <140> TBD <141> 2018-06-28 <150> US 62 / 526,678 <151> 2017-06-29 <160> 31 <170> PatentIn version 3.5 <210> 1 <211> 29 <212> PRT <213> Homo sapiens <400> 1 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 2 <211> 29 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 2 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 <210> 3 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 3 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 4 <211> 33 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 4 Lys Pro Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys 1 5 10 15 Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn 20 25 30 Thr <210> 5 <211> 35 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 5 Lys Pro Lys Pro Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr 1 5 10 15 Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu 20 25 30 Leu Asn Thr 35 <210> 6 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with 12-aminododecanoic acid-12-aminododecanoic acid <400> 6 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 7 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with 12-aminododecanoic acid-12-aminododecanoic acid-Lys-Lys-Lys-Lys-Lys-Lys <400> 7 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 8 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with Lys Lys Lys Lys Lys Lys <400> 8 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 9 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> 8-amino-3,6-dioxaoctanoic acid-functionalized <400> 9 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 10 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> 8-Amino-3,6-dioxaoctanoic acid- 8-Amino-3,6-dioxaoctanoic acid- Lys - Lys - Lys - Lys - Lys - Lys functionalized <400> 10 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 11 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 11 Lys Pro Lys Pro 1 <210> 12 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 12 Lys Pro Lys Pro Lys Pro 1 5 <210> 13 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 13 Lys Lys Lys Lys Lys Lys 1 5 <210> 14 <211> 29 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (29)..(29) <223> The C-terminus is amine-modified <400> 14 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 15 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> 15 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 16 <211> 33 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> The C-terminus is amine-modified <222> (33)..(33) <220> <221> MISC_FEATURE <222> (33)..(33) <223> The C-terminus is amine-modified <400> 16 Lys Pro Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys 1 5 10 15 Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn 20 25 30 Thr <210> 17 <211> 35 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (35)..(35) <223> The C-terminus is amine-modified <400> 17 Lys Pro Lys Pro Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr 1 5 10 15 Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu 20 25 30 Leu Asn Thr 35 <210> 18 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> 18 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 30 <210> 19 <211> 33 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (33)..(33) <223> The C-terminus is amine-modified <400> 19 Lys Pro Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys 1 5 10 15 Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn 20 25 30 Thr <210> 20 <211> 35 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (35)..(35) <223> The C-terminus is amine-modified <400> 20 Lys Pro Lys Pro Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr 1 5 10 15 Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu 20 25 30 Met Asn Thr 35 <210> twenty one <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> twenty one Glu Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> twenty two <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with Lys Lys Lys Lys Lys Lys <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> twenty two Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> twenty three <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with Lys Lys Lys Lys Lys Lys <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> twenty three Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 30 <210> twenty four <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with Lys Lys Lys Lys Lys Lys <400> twenty four Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 30 <210> 25 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> 8-amino-3,6-dioxaoctanoic acid-functionalized <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> 25 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 26 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> 8-amino-3,6-dioxaoctanoic acid- 8-amino-3,6-dioxaoctanoic acid- Lys - Lys - Lys - Lys - Lys functionalized <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> 26 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asn Thr 20 25 30 <210> 27 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with Pro Lys Pro Lys Pro Lys <220> <221> MISC_FEATURE <222> (31)..(31) <223> The C-terminus is amine-modified <400> 27 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 30 <210> 28 <211> 31 <212> PRT <213> Artificial sequence <220> <223> Synthetic <220> <221> MISC_FEATURE <222> (1) <223> Functionalized with Pro Lys Pro Lys Pro Lys <400> 28 Lys Pro His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu 1 5 10 15 Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 30 <210> 29 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 29 Pro Lys Pro Lys Pro Lys 1 5 <210> 30 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 30 Glu ProGlu Pro 1 <210> 31 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic <400> 31 Glu Pro Glu Pro Glu Pro 1 5

Claims

1. A prodrug peptide or a salt thereof having at least one improved biological property compared to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of: therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism, wherein the prodrug peptide has the following structure composition: Z-pep, in: pep is glucagon or an analog thereof; wherein the amino acid sequence of pep is identical to a sequence selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2; Z is located at the N-terminus of pep and is cleaved in vivo to release pep, where the structure of Z is (Lys-Pro) X , and X is an integer from 1 to 5; or Z is selected from the group consisting of EP, EPEP or EPEPEP; and Wherein the first amino acid of Z is functionalized with a soluble compound, wherein the soluble compound is selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

2. The prodrug peptide of claim 1, wherein the C-terminus of the prodrug peptide is amine-modified.

3. The prodrug peptide of claim 1, wherein the structure of Z is: (Lys-Pro) X .

4. The prodrug peptide of claim 1, wherein Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP and KPKPKP.

5. The prodrug peptide of claim 3, wherein X is an integer from 2 to 5, and wherein two Lys of Z are functionalized with soluble compounds, wherein each soluble compound is independently selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

6. The prodrug peptide of claim 1, wherein Z is KPKP or KPKPKP, and wherein two Lys of Z are functionalized with soluble compounds, wherein each soluble compound is independently selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

7. The prodrug peptide of claim 1, wherein X is 1.

8. The prodrug peptide of claim 1, wherein the soluble compound is hydrophilic.

9. The prodrug peptide of claim 1, wherein the structure of Z is (Lys-Pro) X , wherein X is an integer of 2-5, and wherein two Lys of Z are functionalized by soluble compounds, and the soluble compounds are each independently selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

10. The prodrug peptide of claim 1, wherein the amino acid sequence of the pep is identical to a sequence selected from the group consisting of: SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

11. A prodrug peptide or a salt thereof, wherein the prodrug peptide consists of the structure Z-pep, wherein: The amino acid sequence of pep is identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); The C-terminus of the prodrug peptide is amine modified; and Z is attached to the N-terminus of pep and is cleaved in vivo to release pep, where: The structure of Z is (Lys-Pro) X , in, X is an integer from 1 to 5, or Z is selected from the group consisting of EP, EPEP or EPEPEP, and Wherein the first amino acid of Z is functionalized with a soluble compound, wherein the soluble compound is selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

12. The prodrug peptide of claim 11, wherein: The amino acid sequence of pep is identical to that of SEQ ID NO:2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); Z is KP; The lysine of Z is functionalized with a soluble compound via an ε-N bond; and The soluble compound is (Pro-Lys) m , where m is 3.

13. A pharmaceutical composition comprising: an effective amount of the prodrug according to any one of claims 1 to 12, and a pharmaceutically acceptable carrier.

14. Use of a prodrug according to any one of claims 1 to 12 or a pharmaceutical composition comprising the prodrug and a pharmaceutically acceptable excipient or carrier in the preparation of a medicament for treating or preventing hypoglycemia or a hypoglycemia-related disorder or disease in a subject in need thereof, wherein the medicament is effective in treating or preventing hypoglycemia or a hypoglycemia-related disorder or disease.

15. A method for preparing a prodrug peptide or a salt thereof according to any one of claims 1 to 12, wherein the prodrug peptide or a salt thereof has at least one improved biological property compared to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of: therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism, wherein the method include: adding a prodrug moiety to the parent peptide or peptidomimetic, The prodrug part (i) is located at the N-terminus of pep and is cleaved in vivo to release the parent peptide or peptidomimetic, and (ii) has a structure of EP, EPEP, EPEPEP or (Lys-Pro) X , (iii) X is an integer from 1 to 5, and (iv) wherein the first amino acid is functionalized with a soluble compound, wherein the soluble compound is independently selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

16. The method of claim 15, wherein the prodrug moiety has the structure: (Lys-Pro) X .

17. The method of claim 15, wherein the prodrug moiety is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.

18. The method of claim 15, wherein the prodrug moiety is (Lys-Pro) X , x is an integer from 2 to 5, and wherein the two Lys of the prodrug moiety are functionalized with a soluble compound, wherein each soluble compound is independently selected from: (Lys) m and (Pro-Lys) m , where m is an integer from 1 to 5.

19. The method of claim 15, wherein X is 1.

20. The method of claim 15, wherein the soluble compound is water soluble.

21. The method of any one of claims 15 to 20, wherein The amino acid sequence of the parent peptide or peptidomimetic is identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); The first amino acid of the prodrug moiety is functionalized with a soluble compound include: (Lys) m or (Pro-Lys) m , where m is an integer from 1 to 5; The method further comprises amidating the C-terminus of the peptide or modifying the C-terminus of the protein with an amine; or A combination of them.

22. The method of any one of claims 15 to 20, wherein The amino acid sequence of the parent peptide or peptidomimetic is identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); The structure of Z is (Lys-Pro) X ; X is an integer from 2 to 5; and wherein the two Lys groups of the prodrug moiety are functionalized with a soluble compound include: (Lys) m or (Pro-Lys) m , where m is an integer from 1 to 5; The method further comprises amidating the c-terminus of the peptide or modifying the c-terminus of the protein with an amine; or A combination of them.

23. The method of any one of claims 15-20, wherein the amino acid sequence of the parent peptide or peptidomimetic is identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).

24. The method according to any one of claims 15 to 20, in: The amino acid sequence of the parent peptide or peptidomimetic is identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); and The method further comprises amidating the C-terminus of the peptide or modifying the C-terminus of the protein with an amine.

25. The method of claim 15, wherein: The amino acid sequence of the parent peptide or peptidomimetic is identical to the sequence of SEQ ID NO:2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); The prodrug moiety is KP, and the lysine of the prodrug moiety is functionalized with a soluble compound via an ε-N bond; and The soluble compound is (Pro-Lys) m , where m is 3.

26. The method of claim 15, further comprising amidating the C-terminus of the peptide or modifying the C-terminus of the protein with an amine, wherein: The amino acid sequence of the parent peptide or peptidomimetic is identical to the sequence of SEQ ID NO:2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT); The prodrug moiety is KP, and the lysine of the prodrug moiety is functionalized with a soluble compound via an ε-N bond; and The soluble compound is (Pro-Lys) m , where m is 3.